AUTHOR=Wang Lin , Ding Shaowei , Hu Yuxin , Su Jiaming , Zhu Gegongming , Hong Hanzhang , Hou Baoluo , Dong Zhaoxi , Xue Zeyu , Wang Jiayi , Liu Zhongjie , Liu Hongfang , Liu Weijing 

TITLE=Targeting programmed cell death pathways: emerging therapeutic strategies for diabetic kidney disease

JOURNAL=Frontiers in Endocrinology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1513895

DOI=10.3389/fendo.2025.1513895

ISSN=1664-2392

ABSTRACT=Diabetic kidney disease (DKD) is a leading cause of kidney failure. However, its pathogenesis remains incompletely understood, hindering the development of effective treatments. In recent years, substantial evidence has indicated that abnormal programmed cell death (PCD), including apoptosis, pyroptosis, ferroptosis, and autophagy, plays a crucial role in the progression of DKD, particularly in intrinsic renal cells such as podocytes, tubular epithelial cells, and mesangial cells. Novel therapeutic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) receptor agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and relevant traditional Chinese medicines and their formulations, have demonstrated significant efficacy in improving intrinsic renal cell PCD in DKD. This review aims to provide a concise overview of the four types of PCD and their relationship with DKD, with a particular focus on highlighting the therapeutic potential of targeting PCD signaling pathways in the treatment of DKD.